Summary

Aurinia Pharmaceuticals' Phase III (AURORA) design is nearly identical to the promising Phase II (AURA) study.

Advantageous change to Phase III includes: Primary endpoint of complete remission (or renal response) at 52 weeks (as opposed to 24 weeks in Phase II).

Management team will likely enroll healthier patients and limit countries (e.g., Bangladesh and Philippines) with compromised access to medical care.